Evidence map›Paper›PMID 33038626›Full record

ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2020

Neuraminidase characterisation reveals very low levels of antiviral resistance and the presence of mutations associated with reduced antibody effectiveness in the Irish influenza 2018/2019 season.

Carina Brehony, Linda Dunford, Charlene Bennett, Joan O'Donnell, Lisa Domegan, Eleanor McNamara, Cillian F De Gascun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Carina BrehonyPublic Health Laboratory, Health Service Executive, Dublin, Ireland; European Public Health Microbiology Training Programme (EUPHEM), European Centre for Disease Control and Prevention, Stockholm, Sweden. Electronic address: carina.brehony@hse.ie.
Linda DunfordNational Virus Reference Laboratory, University College Dublin, Dublin, Ireland.
Charlene BennettNational Virus Reference Laboratory, University College Dublin, Dublin, Ireland.
Joan O'DonnellHealth Service Executive, Health Protection Surveillance Centre, Dublin, Ireland.
Lisa DomeganHealth Service Executive, Health Protection Surveillance Centre, Dublin, Ireland; European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, Stockholm, Sweden.
Eleanor McNamaraPublic Health Laboratory, Health Service Executive, Dublin, Ireland.
Cillian F De GascunNational Virus Reference Laboratory, University College Dublin, Dublin, Ireland.
Health Service Executive · IEUniversity College Dublin · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuraminidase inhibitor (NAI) resistance levels globally are currently low. However, as antivirals are increasingly being used, and even in the absence of selective pressure, resistance may increase or emerge. The neuraminidase (NA) genes from influenza viruses from the Irish 2018/2019 season were sequenced: 1/144 (0.7 %) A(H1N1)pdm09 sequences harboured a substitution associated with highly-reduced susceptibility to NAIs. The very low NAI resistance we describe supports current Irish NAI use recommendations. However, continued monitoring is essential. NA characterisation also identified substitutions associated with reduced antibody effectiveness, thereby highlighting the potential of NA sequence surveillance as an additional tool for investigating influenza vaccine effectiveness (VE).

Indexed as

Drug Resistance, ViralInfluenza A Virus, H1N1 SubtypeInfluenza, HumanAntiviral AgentsEnzyme InhibitorsHumansIrelandMutationNeuraminidaseOseltamivirSeasonsAntiviral AgentsEnzyme InhibitorsNeuraminidaseOseltamivirAntiviral resistanceInfluenzaIrelandLaboratory surveillanceMolecular epidemiologyVaccine effectiveness

Identifiers

PMID33038626
PMCPMC7527353
OpenAlexW3091054350

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.